HapA protease targets PAR-1/2 to modulate ERK signalling and reduce cancer cell viability
8.0
来源：
Nature
发布时间：
2025-08-29 07:41
摘要：
HapA protease from Vibrio cholerae has been identified as a significant factor in reducing the viability of human epithelial carcinoma cells by cleaving protease-activated receptors PAR-1 and PAR-2. This cleavage modulates the MEK-ERK signaling pathway, leading to apoptosis in cancer cells. The findings suggest that HapA could serve as a novel therapeutic target in cancer treatment, highlighting the potential of bacterial factors in influencing cancer cell behavior and opening new avenues for anticancer therapies.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0分
business_impact
1.0分
scientific_rigor
1.5分
timeliness_innovation
1.5分
investment_perspective
2.5分
market_value_relevance
1.0分
team_institution_background
0.0分
technical_barrier_competition
0.5分
关键证据
HapA cleaves PAR-1/2, triggering apoptosis in cancer cells.
Study reveals novel mechanisms of bacterial protease in cancer treatment.
HapA's role in modulating MEK-ERK signaling pathway is significant.
真实性检查
否
AI评分总结
HapA protease from Vibrio cholerae has been identified as a significant factor in reducing the viability of human epithelial carcinoma cells by cleaving protease-activated receptors PAR-1 and PAR-2. This cleavage modulates the MEK-ERK signaling pathway, leading to apoptosis in cancer cells. The findings suggest that HapA could serve as a novel therapeutic target in cancer treatment, highlighting the potential of bacterial factors in influencing cancer cell behavior and opening new avenues for anticancer therapies.